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Abstract
Introduction: Traditionally, heart bypass surgery has required
stopping of the heart and the use of cardiopulmonary bypass.
Numerous complications have been associated with exposure to
this extracorporeal circuit. Newer techniques of local cardiac wall
stabilization now enable this operation to be performed safely “Off
Pump “. The early clinical results of Off Pump Coronary Artery
Bypass (OPCAB) will be compared to a similar group of traditional
Coronary Artery Bypass Grafting (CABG) patients.
Methods: A retrospective review of 737 consecutive patients
undergoing elective coronary artery bypass grafting was per
formed, 66 of who underwent traditional CABG and 69 of who
underwent OPCAB. Inclusion criteria consisted of first time cardiac
surgical procedures with an ejection fraction 20%, without signifi
cant renal failure (creatinine <2.0).
Results: There was no statistical difference in the age, sex, cardiac
function or underlying co-morbidities between those undergoing
CABG and OPCAB. CABG patients had slightly more vessels
bypassed than those in the OPCAB group (3.0 vs 2.6, p=0.0 10).
Despite similar preoperative characteristics, the OPCAB group
experienced a reduction in morbidity without an increase in mortal
ity.
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Conclusion: In similar patient populations, OPCAB was associ
ated with significantly reduced transfusion requirements, intubation
time, ICU and overall hospital lengths of stay, with no increase in
mortality. Further investigation is warranted to ascertain the role of
the OPCAB in the general cardiac surgical community.
Introduction
With our aging population, ischemic coronary disease is becoming
an increasingly prominent health care problem. Over 800,000
coronary artery bypass grafting operations (CABG) are performed
annually worldwide. Traditionally, CABG is performed with car
diopulmonary bypass (CPB) and global cardiac arrest to create a still
and bloodless operative field. CPB however, can be associated with
significant morbidity and mortality.
Multiple organ systems are deleteriously affected by the systemic
inflammatory response. which ensues following exposure of the
body to CPB. Organs involved include the heart, lungs, central
nervous system. kidneys and gastrointestinal tract.’ Cardiac damage
has been attributed to activated neutrophils, oxygen free radicals and
cytotoxins that cause myocardial edema and decreased contractility.
Pulmonary dysfunction has been attributed to the degradation of
surfactant. activation of complement and neutrophils, and conse
quent increased capillary permeability, interstitial edema, atelecta
sis, and decreased compliance. Neurologic complications such as
stroke and neurocognitive dysfunction may be related to cerebral
microemboli, associated with CPB, aortic cannulation, or surgical
manipulation of the aorta. In one prospective multi-institutional
study of 2108 patients undergoing CABG with CPB, stroke was seen
in 3% overall.2 Risk factors for a stroke following CABG with CPB
included older age (> 70 years old = 6.1% stroke rate), history of a
prior stroke (10.1 % stroke rate), uncontrolled systolic hypertension
(11.0% stroke rate), and chronic obstructive pulmonary disease
(6.1 % stroke rate). In another prospective trial, neurocognitive
dysfunction. which is defined as deterioration in intellectual func
tioning. confusion, agitation. disorientation, or memory deficit, was
seen in 73% of patients following CABG with CPB tested at 8 days
postop. Follow-up testing showed initial improvement at 2 months
(38% had deficit) that seemed to plateau at one year (35% had
deficit).34
Interest in minimizing the trauma of heart surgery has spulTed
investigation into less invasive approaches. The Off Pump Coro
nary Artery Bypass (OPCAB) utilizes new techniques of local
cardiac wall stabilization, which allow accurate suture placement on
the beating heart. All coronary vessels are approachable with this
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Table 1
OPCAB (n=69) CABG (n=681 p-value
Transfusion required 29.0% 45.6% 0,045
Intubation time (hrs) 3.3 ± 7.3 9.5 ± 8.1 <0.001
ICU LOS (days) 1.5 ± 1.0 2.4 ± 3.1 0.027
Hospital LOS (days) 4.9 ± 2.2 6.6 ± 4.2 0.005
CVA 0(0%) 2 (3%) 0.150
Death 0(0%) 2 (3%) 0.150
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operation and the OPCAB completely avoids the need to place the
body on CPB. We will examine the early clinical experience with
this new procedure.
Methods
A retrospective review of consecutive patients undergoing elective
coronary artery bypass grafting was performed. Inclusion criteria
were first time cardiac surgical procedures with ejection fractions
20%, without significant renal dysfunction (creatinine <2.0). In
order to compare patient populations undergoing a similar number
of bypass grafts, all traditional CABG patients who underwent 3
grafts from January 1998 through May 1999 were included. Patient
accrual was from May 1998 through May 1999 (OPCAB), and
January 1998 through May 1999 (CABG). These procedures were
performed at the St. Francis Medical Center at Liliha. Queens
Medical Center, and Kuakini Medical Centers, all located in Hono
lulu, Hawaii. Informed clinical consent was obtained in all cases.
Statistical analysis was performed using SPSS statistical software.
Paired t tests were utilized. Differences at the 95% confidence level
were considered to be statistically significant.
Results
69 OPCAB and 68 CABG patients were compared. There was no
statistical difference in the age (OPCAB 64.8 years, CABG 66.0
years), sex distribution (OPCAB 73% male, CABG 76% male),
estimated ejection fraction (OPCAB 55.5% vs CABG 50.9%) or
underlying co-morbidities between those undergoing OPCAB and
CABG. CABG patients had slightly more vessels bypassed than
those in the OPCAB group (3.0 vs 2.6 p = 0.01). In this series, 10/
68 (14.7%) CABG patients had more than 3 coronary vessels
bypassed (4.4 ± .7 bypass grafts) whereas 11/69 (15.9%) in the
OPCAB group had more than 3 bypasses performed (4.0 ± 0 bypass
grafts). Despite these similar preoperative characteristics, the
OPCAB group experienced reduced morbidity compared to those
undergoing traditional CABG, with no increase in mortality. Inten
sive care unit and overall hospital lengths of stay were also reduced.
(Table 1)
Discussion
Our early experience with the OPCAB has been encouraging. We
have been subjectively impressed with the reduced trauma this
operation seems to be associated with in selected patients. This
study verifies our impression of a more favorable early clinical
result with the OPCAB. The reductions in transfusion require
ments, intubation time, ICU and overall hospital lengths of stay are
tangible benefits both to the patient directly and to society in general,
in terms of reduced medical expenditure and preservation of re
sources.
Of those patients undergoing traditional CABG, 45.6% required
postoperative blood and blood product transfusions. This compares
favorably with the reported 75% transfusion rate in a group of 100
patients undergoing CABG with CPB at a major metropolitan
medical center.5Unfortunately. this rate of blood and blood product
transfusions are not uncommon after coronary bypass surgery and is
attributed largely to the damaging effects of CPB on platelet func
tion, and the coagulation cascade. The necessity for high dose
heparinization as well as the hypothermia associated with traditional
CABG with CPB, are contributing factors as well. In contrast, those
patients undergoing the OPCAB are never subjected to the rigors of
cardiopulmonary bypass. Platelets and clotting function are pre
served. A lower dose of heparin is utilized and the patients are kept
warm throughout the procedure. Accordingly, the reduction in
transfusion requirements with the OPCAB procedure (29.0%) should
not be surising.
The damaging pulmonary effects of CPB can be profound. Pul
monary interstitial edema is common after CPB and requires vigor
ous diuresis and prolonged ventilation. Atelectasis and reduction in
surfactant levels have been associated with CPB and the lack of
ventilation of the lungs during a traditional CABG procedure. In
contrast, the OPCAB patients are ventilated thoughout the entire
procedure and are ready for extubation in many cases almost
immediately. In this series, over 50% of the OPCAB patients were
successfully extubated on the operating room table, at the end of the
procedure.
A significant reduction in ICU and overall hospital lengths of stay
was observed with the OPCAB. The earlier extubation in these
patients, no doubt, speeds time to recovery and allows earlier
ambulation and resumption of normal nutrition. The reduced
pulmonary interstitial fluid allows these patients to wean off of
oxygen more quickly, which can lead to a quicker recovery and
discharge.
Neuro logic sequelae of CABG with CPB can be one of the most
feared complications of this procedure. Stroke can have devastating
effects for the patient, family and society. It is associated with high
in-hospital mortality rates (21% with stroke vs 2% without stroke),
longer hospital stays (25 days with stroke vs 10 days without stroke),
and higher rates of discharge to intermediate care or nursing home
facilities (47% with stroke vs 8% without stroke).2 Neurocognitive
dysfunction is a more subtle neurologic deficit commonly seen after
CABG with CPB. Development of these neurologic complications
have been associated with cerebral microemboli, generated from a
diseased atherosclerotic aorta, from the CPB pump circuit, or
through surgical manipulation of the heart and aorta. These
microemboli can be detected with use of Transcranial Doppler
ultrasound probes placed over the bilateral middle cerebral arteries 6
Since OPCAB avoids CPB entirely; cerebral microemboli may be
reduced with reduced neurologic complications. Interestingly, in
this series no strokes were observed in the OPCAB group whereas
2 documented clinical strokes (3%) were seen in the traditional
CABG group, resulting in one of the two mortalities in this series.
While not reaching statistical significance (p=O. 150), this trend is
supportive of a possible reduction in neurologic complications with
the OPCAB.
Clearly there are significant limitations to this study. While
consecutive, it is retrospective and subject to significant surgeon
selection bias (i.e. perhaps only healthier patients may have had an
OPCAB). We hoped to minimize this by using uniform inclusion
criteria (elective patients. first time cardiac surgery, ejection frac
tion 20 %. no significant renal dysfunction with creatinine < 2.0).
We tried to analyze patients with similar numbers of grafts as well.
We were fairly successful in our efforts. No significant differences
in age, sex or ejection fraction existed between the two groups.
Slightly more grafts were performed in the traditional CABG group
than in the OPCAB group (3.0 vs 2.6, p=O.Ol), however, a greater
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percentage of OPCAB patients (15.9%) had greater than 3 grafts 
performed compared to the traditional CABG group (14.7%). 
Graft patency is an obvious important endpoint not addressed in 
this study. Surgeon selection bias (i.e. perhaps only patients with 
relatively larger target coronary vessels underwent OPCAB) also 
limits useful analysis. We believe that only a properly performed 
prospective randomized trial can adequately answer this question. 
Early angiographic results by others however, have been reported. 
Jansen et al7 in a favorable clinical report of their first 100 patients 
who underwent multivessel OPCAB documented an angiographic 
patency rate of 95%. Calafiore and colleagues in 190 consecutive 
patients and Subramanian in 52 consecutive patients have reported 
angiographic patency rates of 98.9%,8 and 96.2%,9 respectively. 
Not all patients can undergo OPCAB. Anatomic and hemody-
namic considerations play a role as well as the experience of the 
surgical team. In this series, 4 patients (5.5%) initially undergoing 
OPCAB were converted intraoperatively to a traditional CABG. In 
these patients, hemodynamic instability resulted from either lifting 
or stabilizing the heart, necessitating conversion. There were no 
myocardial infarctions or other significant complications in these 
patients. All were discharged home safely with total hospitaliza-
tions ranging from five to nine days (mean 6.5 days). In this study, 
these patients were included in the traditional CABG group for 
analysis. 
Because of these limitations, definitive conclusions regarding the 
role of the 0 PCAB in the general cardiac surgical population cannot 
be made. Surgeon selection bias can only be overcome with a 
prospective randomized clinical trial. We believe, however that 
these results are interesting and warrant further study. Accordingly, 
we have now embarked and are actively enrolling patients into a 
prospective randomized clini,cal trial comparing the OPCAB to 
traditional CABG. Funded by a grant from the Hawaii Community 
Foundation, we are studying the effects of the two procedures on 
neurologic function, morbidity and cost. Pre and postoperative 
neurologic and neurocognitive function, brain perfusion and intra-
operative Transcranial Doppler analysis of cerebral microemboli, 
are important facets of this ongoing clinical trial. 
We believe that the OPCAB is an exciting new procedure, which 
may have much potential. As with any new medical procedure 
however, careful and objective study in the context of a prospective 
randomized protocol should be encouraged. 
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